A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies

NCT00720278 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

526

Enrollment

INDUSTRY

Sponsor class

Conditions

Seasonal Allergic Rhinitis

Interventions

DRUG: 0.15% azelastine hydrochloride 1644 mcg daily
DRUG: 0.1% azelastine hydrochloride 1096 mcg daily
DRUG: Placebo

Sponsor

Meda Pharmaceuticals